FDA Recall Terminated

ARCHITECT AUSAB Reagent list number 1L82-25 has the following components: 1) Architect AUSAB microparticles and 2) Architect AUSAB Conjugate. in vitro diagnostic.

Recall: Z-1096-2007 · Initiated May 14, 2007

Recall

Recall Number
Z-1096-2007
Event Number
37961
Firm
Abbott Diagnostic International, Ltd. 30 Bo Cruce Davila
FEI Number
2623532
Product Code
LOM
Status
Terminated
Root Cause
Other
Initiated
May 14, 2007
Posted
July 24, 2007
Terminated
June 10, 2011
Address
Barceloneta, PR, 00617-3009

Description

ARCHITECT AUSAB Reagent list number 1L82-25 has the following components: 1) Architect AUSAB microparticles and 2) Architect AUSAB Conjugate. in vitro diagnostic.

Reason

During an internal study, the Architect AUSAB assay was found to read preparations of the WHO standard up to 53% higher than the WHO assigned value. This has the potential to cause elevated results and may impact the interpretation for a small percentage of results with grayzone or low-level reactive concentrations and higher proficiency sample results.

Action

All ARCHITECT AUSAB U.S. customers will be contacted. New customers will be contacted through a Product Information Letter that will be included in all ARCHITECT AUSAB Reagent Kits until assay is restandardized. All ARCHITECT AUSAB U.S. customers will be contacted. The following communication types were used: Product Correction Letter Customer Reply Form > Product Information Letter to be included in new kits to be distributed. Letters were sent to customers by Federal Express Priority mail. The Customers were instructed to: Please follow their laboratory procedures for evaluation of these results Disregard the automated interpretation of results for low-level reactive samples. A customer reply form will accompany the Product Correction letter. Effectiveness Check Depth: 100% of customers receiving the Product Correction letter. The start date of communication was May 14,2007.

Distribution

Nationwide and Puerto Rico

Quantity

1494